摘要
目的探讨表柔比星、多西他赛不同联合方案应用于乳腺癌新辅助化疗的临床效果。方法选取150例乳腺癌患者为研究对象,采用非随机同期对照分组法,将采用5-氟尿嘧啶+表柔比星+环磷酰胺序贯联合多西他赛(FEC-T)方案者纳入观察组(n=87),采用多西他赛+表柔比星+环磷酰胺(TEC)方案者纳入对照组(n=63)。比较治疗前及治疗6个周期后,两组生长抑制因子4(ING4)、缺氧诱导因子1α亚基(HIF-1α)阳性率、糖类抗原153(CA153)、肿瘤特异性生长因子(TSGF)水平变化,以及两组治疗效果、生活质量及毒副反应。结果治疗后,两组癌组织ING4表达阳性率均较治疗前升高,HIF-1α表达阳性率及血清CA153、TSGF水平均较治疗前下降,差异有统计学意义(P<0.05),但组间差异无统计学意义(P>0.05);两组治疗效果比较差异无统计学意义(P>0.05);观察组QLQ-BR23评分中系统治疗反应维度评分则明显低于对照组,严重毒副反应发生率亦明显低于对照组,差异均有统计学意义(P<0.05)。结论表柔比星序贯或连续联合多西他赛应用于乳腺癌新辅助化疗治疗效果均较为理想,但序贯联合方案因引起毒副反应较少而安全性更突出,对癌组织恶性程度降低有利。
Objective To explore the clinical effects of different combination regimens of epirubicin and docetaxel in neoadjuvant chemotherapy for breast cancer.Methods One hundred and fifty patients with breast cancer were selected for the study.According to the non-randomized simultaneous control grouping,the patients who received 5-fluorouracil+epirubicin+cyclophosphamide sequential combined with docetaxel(FEC-T)were included in observation group(n=87),and patients who were given docetaxel+epirubicin+cyclophosphamide(TEC)regimen was included in control group(n=63).The positive rates of inhibitor of growth factor 4(ING4)and hypoxia-inducible factor 1αsubunit(HIF-1α)and levels of carbohydrate antigen 153(CA153)and tumor specific growth factor(TSGF)before treatment and after 6 cycles of treatment,treatment effects,quality of life and toxic/side effects were compared between the two groups.Results After treatment,the positive rate of ING4 expression in cancer tissue in the two groups was significantly increased while the positive rate of HIF-1αexpression and serum levels of CA153 and TSGF were significantly decreased than those before treatment(P<0.05),but there were no significant differences between the two groups(P>0.05).There was no significant difference in the treatment effects between the two groups(P>0.05).The score of systemic treatment response in the QLQ-BR23 scale and the incidence rates of severe toxic/side effects were significantly lower in the observation group than those in the control group(P<0.05).Conclrsion Epirubicin sequential therapy or continuous combination with docetaxel has ideal treatment effects in the neoadjuvant chemotherapy for breast cancer.However,sequential combined therapy has less toxic/side effects and is more safety.It is more beneficial to reduce the degree of malignancy of cancer tissues.
作者
王仲臣
王广征
谭亭昭
WANG Zhong-cheng;WANG Guang-zhen;TAN Ting-zhao(Department of Pharmacy,Infectious Disease Hospital,Liaocheng 252000,China;Oncology Department,Infectious Disease Hospital,Liaocheng 252000,China)
出处
《实用医院临床杂志》
2019年第5期87-91,共5页
Practical Journal of Clinical Medicine
